iSpecimen Inc. (ISPC) vs Nuwellis, Inc. (NUWE)
A side-by-side comparison of iSpecimen Inc. and Nuwellis, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
ISPC
iSpecimen Inc.
$1.07HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
NUWE
Nuwellis, Inc.
$0.70HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — ISPC vs NUWE
growth of $100 · dividends reinvested · last 2yISPC -92.8% (-73.2%/yr)NUWE -99.5% (-92.9%/yr)ISPC compounded faster over this window
Log scale — wide-divergence pair
ISPC NUWE
ISPC vs NUWE: by the numbers
- •ISPC is the larger company ($3M vs $3M market cap).
- •Both run net losses; NUWE's is the smaller (-123.38% vs -2449.04% net margin).
- •NUWE grew revenue faster over the past five years (1.48% vs -46.70% CAGR).
Metrics side by side
Valuation
| Metric | ISPC | NUWE |
|---|---|---|
| P/S ratio | 5.78 | 0.28 |
| P/B ratio | 1.55 | N/A |
Profitability
| Metric | ISPC | NUWE |
|---|---|---|
| Gross margin | 1.25% | 69.69% |
| Operating margin | -465.42% | -140.62% |
| Net margin | -2449.04% | -123.38% |
| ROE | -657.69% | N/A |
| ROIC | -476.39% | -238.32% |
Growth (annualized)
| Metric | ISPC | NUWE |
|---|---|---|
| Revenue CAGR (5Y) | -46.70% | 1.48% |
| Total return CAGR (5Y) | -81.14% | N/A |
Frequently asked
- Which has grown faster, ISPC or NUWE?
- Over the past five years, NUWE grew revenue faster — ISPC at a -46.70% CAGR versus NUWE at 1.48%.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.